Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

References

• Agrati A. M., Ambrosi G., Ferraro G., Palmieri G. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: a controlled study. Curr. Tber. Res. 1989; 45: 650–6631. Agrati A. M., Ambrosi G., Ferraro G., Palmieri G. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: a controlled study. Curr. Tber. Res. 1989; 45: 650–663
   Web of Science ®Google Scholar
• Avellone G., Di Garbo V., Panno A. V., Cordova R., Lepore R., Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int. Angiol. 1988; 7: 270–2772. Avellone G., Di Garbo V., Panno A. V., Cordova R., Lepore R., Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int. Angiol. 1988; 7: 270–277
   PubMed Web of Science ®Google Scholar
• Berg K. Effect of gemfibrozil on lipid apoprotein parameters. Res Clin. Forums 1982; 4: 85–923. Berg K. Effect of gemfibrozil on lipid apoprotein parameters. Res Clin. Forums 1982; 4: 85–92
   Google Scholar
• Bruckert E., de Carvalho Sousa J., Giral P., Soria C., Chapman M. J., Caen J., de Gennes J. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia. Atherosclerosis 1989; 75: 129–1344. Bruckert E., de Carvalho Sousa J., Giral P., Soria C., Chapman M. J., Caen J., de Gennes J. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia. Atherosclerosis 1989; 75: 129–134
   PubMed Web of Science ®Google Scholar
• Dacie J., Lewis S. M. Practical Haematology6th edit. Churchill Livingstone, Edinburgh 1984; 230–2335. Dacie J., Lewis S. M. Practical Haematology6th edit. Churchill Livingstone, Edinburgh 1984; 230–233
   Google Scholar
• Dormandy J. A., Hoare E., Khattab A. H., Arrowsmith D. E., Dormandy T. L. Prognostic significance of rheological and biochemical findings in patients with intermittent claudication. Br. Med. J. 1073; 4: 581–5836. Dormandy J. A., Hoare E., Khattab A. H., Arrowsmith D. E., Dormandy T. L. Prognostic significance of rheological and biochemical findings in patients with intermittent claudication. Br. Med. J. 1073; 4: 581–583
   Google Scholar
• Dormandy J. A., Gutteridge J. M. C., Hoare E., Dormandy T. L. Effect of clofibrate on blood viscosity in intermittent claudication. Bt. Med. J. 1974; 4: 259–2627. Dormandy J. A., Gutteridge J. M. C., Hoare E., Dormandy T. L. Effect of clofibrate on blood viscosity in intermittent claudication. Bt. Med. J. 1974; 4: 259–262
   PubMed Web of Science ®Google Scholar
• Duffield R. G., Lewis B., Miller N. E., Jamieson C. W., Brunt J. N. H., Colchester A. C. F. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. Lancet 1983; 2: 639–6428. Duffield R. G., Lewis B., Miller N. E., Jamieson C. W., Brunt J. N. H., Colchester A. C. F. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. Lancet 1983; 2: 639–642
   PubMed Web of Science ®Google Scholar
• El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A. Y., Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J. Lipid Res. 1989; 30: 627–6299. El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A. Y., Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J. Lipid Res. 1989; 30: 627–629
   PubMed Web of Science ®Google Scholar
• European Atherosclerosis Society Study Group. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur. Heart J. 1988; 9: 571–60010. European Atherosclerosis Society Study Group. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur. Heart J. 1988; 9: 571–600
   PubMed Web of Science ®Google Scholar
• Frick M. H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 1987; 317: 1237–124511. Frick M. H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 1987; 317: 1237–1245
   PubMed Web of Science ®Google Scholar
• Greenhalgh R. M., Lewis B., Rosengarten D. S., Calnan J. S., Mervart I., Martin P. Serum lipids and lipoproteins in peripheral vascular disease. Lancet 1971; 2: 947–95012. Greenhalgh R. M., Lewis B., Rosengarten D. S., Calnan J. S., Mervart I., Martin P. Serum lipids and lipoproteins in peripheral vascular disease. Lancet 1971; 2: 947–950
   PubMed Web of Science ®Google Scholar
• Hodges R., Marcus E. Safety of gemfibrozil (Lopid) in clinical use. Res. Clin. Forums 1982; 4: 35–4213. Hodges R., Marcus E. Safety of gemfibrozil (Lopid) in clinical use. Res. Clin. Forums 1982; 4: 35–42
   Google Scholar
• Jurgens G., Ashy A., Zenker G. Raised serum lipoprotein during treatment with lovastatin. Lancet 1989; 1: 911–91214. Jurgens G., Ashy A., Zenker G. Raised serum lipoprotein during treatment with lovastatin. Lancet 1989; 1: 911–912
   PubMed Web of Science ®Google Scholar
• Kaukola S., Malkonen M., Koshinen P. Long-term treatment with gemfibrozil in male survivors of myocardial infarction. Further Progress with Gemfibrozil. International Congress and Symposium Series No. 87, R. Soc. Med. Services, London 1986; 35–4015. Kaukola S., Malkonen M., Koshinen P. Long-term treatment with gemfibrozil in male survivors of myocardial infarction. Further Progress with Gemfibrozil. International Congress and Symposium Series No. 87, R. Soc. Med. Services, London 1986; 35–40
   Google Scholar
• Leschke M., Hoffken H., Martin J., Motz W., Strauer B. E. Improved blood fluidity and myocardial microcirculation due to fenofibrate therapy. Clin. Hemorheol. 1989; 9: 494(A)16. Leschke M., Hoffken H., Martin J., Motz W., Strauer B. E. Improved blood fluidity and myocardial microcirculation due to fenofibrate therapy. Clin. Hemorheol. 1989; 9: 494(A)
   Google Scholar
• Loeper J., Emerit J., Goy J., Bedu O., Loeper J. Lipid peroxidation during human atherosclerosis. I.R.C.S. Med. Sci. 1983; 11: 1034–103517. Loeper J., Emerit J., Goy J., Bedu O., Loeper J. Lipid peroxidation during human atherosclerosis. I.R.C.S. Med. Sci. 1983; 11: 1034–1035
   Google Scholar
• Maxwell R. E., Nawrocki J. W., Uhlendorf P. D. Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats. Atherosrclerosis 1983; 48: 195–20318. Maxwell R. E., Nawrocki J. W., Uhlendorf P. D. Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats. Atherosrclerosis 1983; 48: 195–203
   PubMed Web of Science ®Google Scholar
• Meade T. W., North W. R. S., Chakrabarti R., et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050–105419. Meade T. W., North W. R. S., Chakrabarti R., et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050–1054
   PubMed Web of Science ®Google Scholar
• Mitropoulos K. A., Miller G. J., Reeves B. E. A., Wilkes H. C., Cruickshank J. K. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203–20820. Mitropoulos K. A., Miller G. J., Reeves B. E. A., Wilkes H. C., Cruickshank J. K. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203–208
   PubMed Web of Science ®Google Scholar
• Ninrt G., Bulgarelli A., Cassader M., Pagano G. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 71: 113–11921. Ninrt G., Bulgarelli A., Cassader M., Pagano G. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 71: 113–119
   PubMed Web of Science ®Google Scholar
• Nishigaki I., Hagihara M., Tsunekawa H., Maseki M., Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem. Med. 1981; 25: 373–37822. Nishigaki I., Hagihara M., Tsunekawa H., Maseki M., Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem. Med. 1981; 25: 373–378
   PubMed Web of Science ®Google Scholar
• Olsson A. G., Erikson U., Helmius G., Hemmingsson A., Ruhn G. The effect of pronounced serum lipid lowering for one year on the development of femoral atherosclerosis in asymptomatic hyperlipoproteinaemia. Atherosclerosis 1986; 7: 89–9423. Olsson A. G., Erikson U., Helmius G., Hemmingsson A., Ruhn G. The effect of pronounced serum lipid lowering for one year on the development of femoral atherosclerosis in asymptomatic hyperlipoproteinaemia. Atherosclerosis 1986; 7: 89–94
   Google Scholar
• Samuel P. Efficacy of gemfibrozil as a lipid regulator in a patient population in the United States. Vasc. Med. 1984; 2: 8–1524. Samuel P. Efficacy of gemfibrozil as a lipid regulator in a patient population in the United States. Vasc. Med. 1984; 2: 8–15
   Google Scholar
• Sorisky A., Ooi T. C., Simo I. E., Meuffels M., Hindmarsh J. T., Nair R. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis. 1987; 67: 181–18925. Sorisky A., Ooi T. C., Simo I. E., Meuffels M., Hindmarsh J. T., Nair R. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis. 1987; 67: 181–189
   PubMed Web of Science ®Google Scholar
• Stone M. C., Thorpe J. M. Plasma fibrinogen— a major coronary risk factor. J. R. Coll. Gen. Pract. 1985; 35: 565–56926. Stone M. C., Thorpe J. M. Plasma fibrinogen— a major coronary risk factor. J. R. Coll. Gen. Pract. 1985; 35: 565–569
   PubMedGoogle Scholar
• Stringer M. D., Gorog P. G., Freeman A., Kakkar V. V. Lipid peroxides and atherosclerosis. Bi. Med. J. 1989; 298: 281–28427. Stringer M. D., Gorog P. G., Freeman A., Kakkar V. V. Lipid peroxides and atherosclerosis. Bi. Med. J. 1989; 298: 281–284
   PubMed Web of Science ®Google Scholar
• Szamosi T., Gari I., Venekei I., Javor A., Ceskel R., Knoll J. Serum lipids, lipid peroxides and the care of children with high risk atherosclerotic family history. Atherosclerosis. 1987; 68: 111–11528. Szamosi T., Gari I., Venekei I., Javor A., Ceskel R., Knoll J. Serum lipids, lipid peroxides and the care of children with high risk atherosclerotic family history. Atherosclerosis. 1987; 68: 111–115
   PubMed Web of Science ®Google Scholar
• Vessby B., Lithell H., Boberg J., Hellsing K., Werner I. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial. Proc. R. Soc. Med. 1976; 69(Suppl. 2)32–3729. Vessby B., Lithell H., Boberg J., Hellsing K., Werner I. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial. Proc. R. Soc. Med. 1976; 69(Suppl. 2)32–37
   PubMedGoogle Scholar
• Vessby B., Boberg M., Lithell H. Influence of gemfibrozil on lipoprotein composition: triglyceride removal capacity and fatty acid composition of the plasma lipid esters. Further Progress with Gemfibrozil. International Congress and Symposium Series No. 87, R. Soc. Med. Services, London 1986; 1–1030. Vessby B., Boberg M., Lithell H. Influence of gemfibrozil on lipoprotein composition: triglyceride removal capacity and fatty acid composition of the plasma lipid esters. Further Progress with Gemfibrozil. International Congress and Symposium Series No. 87, R. Soc. Med. Services, London 1986; 1–10
   Google Scholar
• Wade C. R., van Rij A. M. Plasma malondialdehyde, lipid peroxides, and the thiobarbituric acid reaction. Clin. Chem. 1989; 35: 33631. Wade C. R., van Rij A. M. Plasma malondialdehyde, lipid peroxides, and the thiobarbituric acid reaction. Clin. Chem. 1989; 35: 336
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 1984; 311: 501–50532. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 1984; 311: 501–505
   PubMed Web of Science ®Google Scholar